These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 18690498)

  • 1. The definition of non-responder to multiple sclerosis treatment: neuroimaging markers.
    Rovaris M
    Neurol Sci; 2008 Sep; 29 Suppl 2():S222-4. PubMed ID: 18690498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Definition of responder: introduction.
    Comi G
    Neurol Sci; 2008 Sep; 29 Suppl 2():S209-10. PubMed ID: 18690493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurophysiological markers.
    Leocani L; Comi G
    Neurol Sci; 2008 Sep; 29 Suppl 2():S218-21. PubMed ID: 18690497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of MRI as an outcome measure in clinical trials.
    Li DK; Li MJ; Traboulsee A; Zhao G; Riddehough A; Paty D
    Adv Neurol; 2006; 98():203-26. PubMed ID: 16400836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the response to multiple sclerosis treatment: the role of conventional magnetic resonance imaging.
    Rovaris M; Filippi M
    Neurol Sci; 2005 Dec; 26 Suppl 4():S204-8. PubMed ID: 16388359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study.
    Chiu AW; Richert N; Ehrmantraut M; Ohayon J; Gupta S; Bomboi G; Gaindh D; Cantor FK; Frank JA; McFarland HF; Bagnato F
    Arch Neurol; 2009 Jan; 66(1):39-43. PubMed ID: 19001157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definition of non-responders: biological markers.
    Furlan R
    Neurol Sci; 2008 Sep; 29 Suppl 2():S214-5. PubMed ID: 18690495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of MRS and fMRI in multiple sclerosis.
    Tartaglia MC; Arnold DL
    Adv Neurol; 2006; 98():185-202. PubMed ID: 16400835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of glatiramer acetate in the treatment of multiple sclerosis.
    Wolinsky JS
    Adv Neurol; 2006; 98():273-92. PubMed ID: 16400839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New options for early treatment of multiple sclerosis.
    Tintoré M
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S9-S11. PubMed ID: 19200870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining multiple sclerosis treatment response with magnetic resonance imaging: how much activity is too much?
    Giacomini PS; Arnold DL; Bar-Or A; Antel JP
    Arch Neurol; 2009 Jan; 66(1):19-20. PubMed ID: 19139295
    [No Abstract]   [Full Text] [Related]  

  • 12. Magnetic resonance imaging in multiple sclerosis.
    Napoli SQ; Bakshi R
    Rev Neurol Dis; 2005; 2(3):109-16. PubMed ID: 16400309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnosis of multiple sclerosis.
    Lublin FD
    Curr Opin Neurol; 2002 Jun; 15(3):253-6. PubMed ID: 12045721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI features of benign multiple sclerosis: toward a new definition of this disease phenotype.
    Rovaris M; Barkhof F; Calabrese M; De Stefano N; Fazekas F; Miller DH; Montalban X; Polman C; Rocca MA; Thompson AJ; Yousry TA; Filippi M
    Neurology; 2009 May; 72(19):1693-701. PubMed ID: 19433744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients.
    Minneboo A; Uitdehaag BM; Ader HJ; Barkhof F; Polman CH; Castelijns JA
    Neurology; 2005 Jul; 65(1):56-61. PubMed ID: 16009885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of modern magnetic resonance techniques to monitor disease evolution in multiple sclerosis.
    Filippi M; Rocca MA
    Adv Neurol; 2006; 98():167-83. PubMed ID: 16400834
    [No Abstract]   [Full Text] [Related]  

  • 17. The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials.
    Martinelli Boneschi F; Rovaris M; Comi G; Filippi M
    Mult Scler; 2004 Aug; 10(4):341-7. PubMed ID: 15327027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI as a marker for disease heterogeneity in multiple sclerosis.
    Bielekova B; Kadom N; Fisher E; Jeffries N; Ohayon J; Richert N; Howard T; Bash CN; Frank JA; Stone L; Martin R; Cutter G; McFarland HF
    Neurology; 2005 Oct; 65(7):1071-6. PubMed ID: 16217061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis.
    Frohman EM; Havrdova E; Lublin F; Barkhof F; Achiron A; Sharief MK; Stuve O; Racke MK; Steinman L; Weiner H; Olek M; Zivadinov R; Corboy J; Raine C; Cutter G; Richert J; Filippi M
    Arch Neurol; 2006 Apr; 63(4):614-9. PubMed ID: 16606781
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical markers of therapeutic response to disease modifying drugs.
    Pozzilli C; Prosperini L
    Neurol Sci; 2008 Sep; 29 Suppl 2():S211-3. PubMed ID: 18690494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.